The Experience of the Cancer Team @ LPBI using NewOncology Cancer Drugs and Clinical Trials Relational Database
Reporter: Aviva Lev-Ari, PhD, RN
Input from LPBI’s Cancer Team
Dr. Williams
1) What is your personal view on the nMOK DB potential for a buyer
The New Medicine Oncology Knowledge Database is a comprehensive, bio-curated, relational database of currently approved chemotherapeutic agents, including up-to-date clinical trial information on chemotherapeutics, their mechanisms of action, and their cellular targets and clinically relevant biomarkers. The need for relational databases, such as the one developed here, has grown both for clinicians, oncologists, their patients, and scientists, in order to communicate information, determine proper therapy, and determine new lines of research.
The nMOK database has an extensive search feature which allows for user-adjusted criteria, such as searching for specific tumor type, mechanism of action, cellular target, combination regimen, etc. This is an essential function for curation purposes, as outlined in point 2, and an imperative resource for clinicians. As nMOK has an established client listing, and the current ability to integrate various biocuration databases with nMOK, a buyer would have multiple avenues for commercialization, not just access to individual clients/organizations.
2) What synergies do you see between the DB and OURS?
I have outlined articles, from our venture, which have incorporated the nMOK database feature to enhance the scientific literature curation process and add value to literature/scientific review. In each case, authors had used their expertise to incorporate scientific analysis of a topic with relevant information obtained from nMOK database searches. These are examples of a synergism between scientific curation, biocuration, and clinical databases. In addition, in a soon-to-be published article, there is a need by mobile health companies for medical and scientific curated information in which teams of scientists and clinicians (curators) add their expert analysis as a value-added for purposes of medical communication and education.
In Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencingauthor Stephen J. Williams, Ph.D. used the New Medicine Oncology Knowledge Base (at http://www.nmok.net) in his discussion of Dr. Charles Swanton’s discovery on the genetic complexity of solid renal tumors, the clonal evolution of the resultant metastases, and varied clinical response to the mTOR inhibitor everolimus. A table was generated using the database to discuss the mechanism of action, various clinical trials, and possible down-stream effects of everolimus.
In Differentiation Therapy – Epigenetics Tackles Solid Tumors, author Stephen J. Williams, Ph.D. wrote on the mechanisms and utility of histone deacetylase inhibitors (HDACi) as chemotherapeutic agents against various solid tumors. Data was taken from the New Medicine Oncology Knowledge Base (at http://www.nmok.net) to formulate a table of Ongoing Cancer Clinical Trials with HDAC Inhibitors, a listing of some clinical trials using histone deacetylase inhibitors in combination with approved chemotherapeutics in various tumors.
Other articles which used the New Medicine Oncology Knowledge Base included on
http://pharmaceuticalintelligence.com as a representation of collaboration and resource sharing between
NEW MEDICINE, INC. AND Leaders in Pharmaceutical Business Intelligence
Author and Curator: Ritu Saxena, Ph.D.
Curator: Ritu Saxena, Ph.D.
Author: Ziv Raviv PhD
Author: Ziv Raviv, PhD
Dr. SAG
- DB has a content like a newspaper/biospace on oncology where they provide up to date info on what is going on in the market. However, they do not have the strong scientific writing piece like OUR’s.
- DB looks like working on a focus area for a fee to provide information but our team has multidisciplinary advantage.
- We have categories in this field since we have a system approach. Cardiovascular, signaling, genomics are the few we include cancer. So how are we going to separate oncology is the key.
- We can use this opportunity for the complied work on cancer for volume 1 and 2. Thus, we can see if there is a benefit.
- If we write for them we should be able to post as Pharmaceutical Intelligence on our website?
- Yet, since the DB has a paid service this may not be the case.
- Also, DB can advertise OUR website on their webpage for the other area of expertise.
Dr. Tilda Barliya
On Cancer Data Base (DB)
“I have used the nmOK database for one of my posts and found it very useful. The DB is highly comprehensive and well-organized which enables flow of information. It allows one to compare the information for different drugs and their clinical trials status. I believe this DB can be used by physicians, researchers as well as the pharmaceutical and Investment companies”.
Leave a Reply